Abstract
Immunoparesis is the suppression of polyclonal immunoglobulins (Igs) and is present in about 85% of patients diagnosed of multiple myeloma (MM). Our group recently demonstrated that the normalization of polyclonal Igs after ASCT is a predictor factor for longer progression-free survival (PFS) and overall survival (OS). However, the impact of this factor in patients who are ASCT-ineligible has not been determined yet.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
